Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24469149 | 0.89 | CNR1 (0.33) | POLBIRAK4 | |
| SCHEMBL2462679 | 0.79 | ALOX15 (0.42) | ALOX15MEN1KMT2APLAUPIM1 | |
| SCHEMBL30467658 | 0.78 | POLB (0.33) | POLBSLC6A4 | |
| SCHEMBL24252315 | 0.78 | POLB (0.33) | POLBSLC6A4 | |
| SCHEMBL24469182 | 0.76 | PRKAA2 (0.39) | SLC6A4 | |
| SCHEMBL30451573 | 0.74 | ALOX15 (0.38) | ALOX15MEN1KMT2APLAUPIM1 | |
| SCHEMBL26732579 | 0.74 | ALOX15 (0.38) | ALOX15MEN1KMT2APLAUPIM1 | |
| SCHEMBL24469158 | 0.71 | DRD2 (0.40) | KMT2A | |
| SCHEMBL23526025 | 0.71 | SOS1 (0.39) | MPOALOX15MEN1KMT2APLAU | |
| SCHEMBL15819555 | 0.70 | POLB (0.46) | POLBMPOMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| EP-4251273-B1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-12 | — | — | EP | disclosed |
| US-20240002371-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-04 | — | — | US | disclosed |
| EP-4251273-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-10-04 | — | — | EP | disclosed |
| CN-116745284-A | Phthalazine derivatives as P2X3 inhibitors | 奇斯药制品公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2022112493-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022112493-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | P2RX3, P2RX5, P2RX7 | POLB 4446/4885MPO 2231/4885SLC6A4 1428/4885 |
| US-20240002371-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX2 | POLB 4386/4885MPO 1970/4885SLC6A4 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.